亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in China: A retrospective, real-world study.

伦瓦提尼 医学 肝细胞癌 内科学 胃肠病学 不利影响 回顾性队列研究 肿瘤科 索拉非尼
作者
Xin‐Rong Yang,De‐Zhen Guo,Fei-Yu Chen,Jia Fan,Zhou Jian
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:39 (15_suppl): e16182-e16182 被引量:1
标识
DOI:10.1200/jco.2021.39.15_suppl.e16182
摘要

e16182 Background: Hepatocellular carcinoma (HCC) is one of the most common malignancy with dismal outcomes. Recently, lenvatinib have been approved as the first-line therapy for unresectable HCC. However, the efficacy and safety of lenvatinib with the combination of other therapy such as transarterial chemoembolization (TACE) and immune checkpoint inhibitor (ICI) therapy was still unclear. Methods: A multicenter retrospective study was conducted and 158 HCC patients treated with lenvatinib from four medical centers were enrolled between November 2018 and December 2020. According to the treatment combined with lenvatinib, all patients were classified into four groups, including lenvatinib monotherapy (LEN) group, combined ICI (c-ICI) group, combined TACE (c-TACE) group and combined ICI and TACE (c-ICI-TACE) group. Objective response rate (ORR) and disease control rate (DCR) were assessed. Overall survival (OS) and time to progression (TTP) were calculated and compared among different groups. Results: All patients (n = 158) were classified into LEN group (n = 40), c-ICI group (n = 42), c-TACE group (n = 39) and c-TACE-ICI group (n = 37). In all patients, the ORR and DCR was 29.1% and 74.1%. The median OS and TTP were 21.8 and 6.2 months, respectively. Four groups showed significant differences in ORR and DCR rates. Specifically, c-ICI-TACE group have significantly higher ORR and DCR rate compared with LEN group (ORR: 12% vs. 38%, P = 0.002; DCR: 60% vs. 89%, P = 0.004). Kaplan-Meier analysis identified that LEN group, c-ICI group, c-TACE group and c-TACE-ICI group showed significantly different TTP (median TTP: 5.0 vs. 6.6 vs. 4.9 vs. 9.5 months; P = 0.021), but similar OS (median OS: 21.8 vs. 19.6 vs. 17.5 months vs. unreached; P = 0.180). Further investigation revealed lenvatinib combined with ICI could prolong TTP compare with lenvatinib without ICI (median TTP: 8.4 vs. 5.0 months; P = 0.019), but it had no significant impact on OS (median OS: unreached vs. 20.1 months; P = 0.300). c-ICI-TACE group showed both better TTP and improved OS compared with other three groups (median TTP: 9.5 vs. 5.2 months; P = 0.004; median OS: unreached vs. 20.1 months; P = 0.034). Univariate and multivariate analysis confirmed that c-ICI-TACE was an independent protective factor for OS (hazard ratio: 0.226; 95% confidence interval: 0.10-0.50; P < 0.001) and TTP (hazard ratio: 0.55; 95% confidence interval: 0.32-0.95; P = 0.032). Most patients (152/158, 96.2%) showed adverse events (AEs) during lenvatinib treatment and the grade 3 AE occurred in 45 patients (28.5%). No significant difference of AE (P = 0.569) and grade 3 AE (P = 0.572) was found among four groups. Conclusions: Lenvatinib was an effective treatment for patients with HCC. Lenvatinib combined ICI could prolong the TTP, while lenvatinib combined ICI and TACE could improve both TTP and OS. Combined therapy wouldn’t escalate the AE and grade 3 AE rates.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
盐水菠萝发布了新的文献求助10
1秒前
29秒前
Junex完成签到,获得积分10
29秒前
无限寒珊完成签到,获得积分10
32秒前
欣喜寒烟发布了新的文献求助10
34秒前
标致的忆梅完成签到,获得积分10
37秒前
42秒前
灵剑山发布了新的文献求助10
48秒前
研友_nxw2xL完成签到,获得积分0
53秒前
充电宝的应助被科研通管家采纳,获得10
59秒前
香蕉觅云的应助被科研通管家采纳,获得10
59秒前
1分钟前
1分钟前
细心慕凝发布了新的文献求助10
1分钟前
欣喜香菇发布了新的文献求助10
1分钟前
Ava的应助被欣喜香菇采纳,获得10
1分钟前
Bowman完成签到,获得积分0
1分钟前
如意紫翠完成签到,获得积分10
1分钟前
细心慕凝完成签到,获得积分10
1分钟前
LHY完成签到,获得积分10
2分钟前
2分钟前
香蕉乐曲完成签到,获得积分10
2分钟前
2分钟前
null的应助被科研通管家采纳,获得10
3分钟前
沉静的愫完成签到,获得积分10
3分钟前
3分钟前
ww完成签到,获得积分10
3分钟前
ww发布了新的文献求助10
3分钟前
3分钟前
adgn发布了新的文献求助10
3分钟前
老实的石头完成签到,获得积分10
4分钟前
4分钟前
个性鹭洋完成签到,获得积分10
4分钟前
丘比特的应助被adgn采纳,获得10
4分钟前
4分钟前
戴肉肉完成签到 ,获得积分10
4分钟前
深情安青的应助被科研通管家采纳,获得10
4分钟前
专注湘完成签到,获得积分10
5分钟前
范特西完成签到 ,获得积分10
5分钟前
忍冬完成签到,获得积分10
5分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173069
求助须知:如何正确求助?哪些是违规求助? 9565519
关于积分的说明 21780383
捐赠科研通 7765085
什么是DOI,文献DOI怎么找? 3431528
关于科研通互助平台的介绍 2555638
邀请新用户注册赠送积分活动 2476668